Theralase Technologies (TLT) Q4 2024 earnings summary

Executive summary

• Annual revenue for 2024 was CAD 1,033,000 (or $1.03M), a 3% decrease year-over-year, with gross margin at 53–54% due to prior inventory write-downs.

• Net loss for 2024 was CAD 4,256,000 ($4.26M), down 7% from 2023, mainly due to reduced R&D spending in the Drug Division.

• The company is advancing a Phase II bladder cancer clinical study, with 79 of 90 patients enrolled and strong efficacy and safety results reported.

• Study II interim data show a 62.5% complete response rate in BCG-unresponsive NMIBC patients, with 45% maintaining response at 12 months and 26.1% at 3 years.

• Ongoing research collaborations and new preclinical data support pipeline expansion in oncology and infectious diseases.

Financial highlights

• Revenue for 2024 was $1,033,431, down 3% from 2023.

• Gross margin improved to 54% of revenue.

• Selling expenses rose 27% due to higher sales salaries and advertising.

• Administrative expenses fell 9% to CAD 1,734,000, with stock-based compensation down 12%.

• Drug Division R&D expenses dropped 12% to CAD 2,578,000, while Device Division R&D rose 300–400%.

Outlook and guidance

• Study II enrollment expected to complete by mid-2025.

• Estimated cost to complete Phase II bladder cancer study is CAD 15–30 million over three years.

• Plans to secure a CAD 100 million base shelf prospectus to fund ongoing and future clinical studies.

• Additional CAD 10 million in debt/equity and government grants/loans targeted to meet eligibility.

• Phase Ib studies for brain and lung cancer estimated at CAD 5 million each, to be funded via the base shelf.